198 related articles for article (PubMed ID: 38565117)
21. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
Front Immunol; 2018; 9():1878. PubMed ID: 30158932
[TBL] [Abstract][Full Text] [Related]
22. Companion diagnostic testing for targeted cancer therapies: an overview.
Fan YS
Genet Test Mol Biomarkers; 2013 Jul; 17(7):515-23. PubMed ID: 23574530
[TBL] [Abstract][Full Text] [Related]
23. KRAS Inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond.
Nagasaka M; Potugari B; Nguyen A; Sukari A; Azmi AS; Ou SI
Cancer Treat Rev; 2021 Dec; 101():102309. PubMed ID: 34715449
[TBL] [Abstract][Full Text] [Related]
24. Novel targeted therapies and immunotherapy for advanced thyroid cancers.
Naoum GE; Morkos M; Kim B; Arafat W
Mol Cancer; 2018 Feb; 17(1):51. PubMed ID: 29455653
[TBL] [Abstract][Full Text] [Related]
25. KRAS mutated colorectal cancers with or without PIK3CA mutations: Clinical and molecular profiles inform current and future therapeutics.
Voutsadakis IA
Crit Rev Oncol Hematol; 2023 Jun; 186():103987. PubMed ID: 37059275
[TBL] [Abstract][Full Text] [Related]
26. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
27. [A decade of checkpoint inhibitors: current standard of care and future trends].
Reischer A; Kruger S; von Bergwelt-Baildon M
Dtsch Med Wochenschr; 2021 Sep; 146(17):1108-1118. PubMed ID: 34448187
[TBL] [Abstract][Full Text] [Related]
28. Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies.
Caughey BA; Strickler JH
Drugs; 2024 Jan; 84(1):27-44. PubMed ID: 38109010
[TBL] [Abstract][Full Text] [Related]
29. Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma.
DeLeon TT; Ahn DH; Bogenberger JM; Anastasiadis PZ; Arora M; Ramanathan RK; Aqel BA; Vasmatzis G; Truty MJ; Oklu R; Bekaii-Saab TS; Borad MJ
Future Oncol; 2018 Mar; 14(6):553-566. PubMed ID: 29460642
[TBL] [Abstract][Full Text] [Related]
30. Immune Checkpoint Inhibitors in the Treatment of Gastrointestinal Malignancies: A Review of Current and Future Therapies.
Hsu A; Mendelson L; Almhanna K
R I Med J (2013); 2020 Apr; 103(3):33-37. PubMed ID: 32236159
[TBL] [Abstract][Full Text] [Related]
31. Drug-biomarker co-development in oncology - 20 years and counting.
Twomey JD; Brahme NN; Zhang B
Drug Resist Updat; 2017 Jan; 30():48-62. PubMed ID: 28363335
[TBL] [Abstract][Full Text] [Related]
32. ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients.
Pearson ADJ; Rossig C; Lesa G; Diede SJ; Weiner S; Anderson J; Gray J; Geoerger B; Minard-Colin V; Marshall LV; Smith M; Sondel P; Bajars M; Baldazzi C; Barry E; Blackman S; Blanc P; Capdeville R; Caron H; Cole PD; Jiménez JC; Demolis P; Donoghue M; Elgadi M; Gajewski T; Galluzzo S; Ilaria R; Jenkner A; Karres D; Kieran M; Ligas F; Lowy I; Meyers M; Oprea C; Peddareddigari VGR; Sterba J; Stockman PK; Suenaert P; Tabori U; van Tilburg C; Yancey T; Weigel B; Norga K; Reaman G; Vassal G
Eur J Cancer; 2020 Mar; 127():52-66. PubMed ID: 31986450
[TBL] [Abstract][Full Text] [Related]
33. Immune checkpoint therapy in liver cancer.
Xu F; Jin T; Zhu Y; Dai C
J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754
[TBL] [Abstract][Full Text] [Related]
34. The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond.
Zhu Z; Liu W; Gotlieb V
Crit Rev Oncol Hematol; 2016 Mar; 99():91-9. PubMed ID: 26708040
[TBL] [Abstract][Full Text] [Related]
35. Updates in the use of targeted therapies for the treatment of cholangiocarcinoma.
Lodl E; Ramnaraign B; Sahin I; Wheeler S
J Oncol Pharm Pract; 2023 Jul; 29(5):1206-1217. PubMed ID: 37097888
[TBL] [Abstract][Full Text] [Related]
36. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer.
Ye F; Dewanjee S; Li Y; Jha NK; Chen ZS; Kumar A; Vishakha ; Behl T; Jha SK; Tang H
Mol Cancer; 2023 Jul; 22(1):105. PubMed ID: 37415164
[TBL] [Abstract][Full Text] [Related]
37. Systemic Therapy for Primary Liver Tumors: Cholangiocarcinoma and Hepatocellular Carcinoma.
Sadeghi S; Bejjani A; Finn RS
Surg Oncol Clin N Am; 2019 Oct; 28(4):695-715. PubMed ID: 31472914
[TBL] [Abstract][Full Text] [Related]
38. The Path to Personalized Treatment in KRAS-Mutant Non-Small Cell Lung Cancer: A Review of Targeted Therapies and Immunotherapy.
Shu CL; Liu YL
Cancer Manag Res; 2022; 14():3485-3492. PubMed ID: 36561983
[TBL] [Abstract][Full Text] [Related]
39. Biomarkers for immune therapy in gastrointestinal cancers.
Weinberg BA; Hameed R; Marshall JL
Clin Adv Hematol Oncol; 2019 Feb; 17(2):109-119. PubMed ID: 30845114
[TBL] [Abstract][Full Text] [Related]
40. Novel targeted treatment options for advanced cholangiocarcinoma.
Mahipal A; Kommalapati A; Tella SH; Lim A; Kim R
Expert Opin Investig Drugs; 2018 Sep; 27(9):709-720. PubMed ID: 30124336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
